Core Viewpoint - The successful mass production of Scandium-44 (Sc-44) in China marks a significant advancement in the field of radiopharmaceuticals, providing a higher resolution and more convenient imaging agent for tumor diagnosis and treatment [1][3]. Group 1: Production Process - The research team at the Jinan Institute of Nuclear Technology has achieved the production of Sc-44 with an activity level in the hundred millicurie range and a nuclear purity greater than 99% [1]. - The production process involves using a cyclotron to bombard natural calcium nitrate targets, resulting in the extraction of Sc-44 from calcium-44 [3]. - The team innovated the target preparation process and developed a purification workflow, conducting over 50 full-process experiments and thousands of data simulations over 700 days [5]. Group 2: Comparison with Existing Isotopes - Currently, the most commonly used radioactive isotope in clinical settings is Fluorine-18 (F-18), which has a half-life of only 110 minutes, necessitating immediate production and delivery [9]. - Gallium-68 (Ga-68), another commonly used isotope, has a half-life of 68 minutes and is limited to on-site preparation or short-distance transport [9]. - In contrast, Sc-44 has a half-life of approximately 4.04 hours, allowing for more flexible production and distribution, making it a superior imaging agent [11]. Group 3: Advantages of Sc-44 - Sc-44 offers higher imaging quality due to its lower positron energy compared to Ga-68, making it a more effective tool for tumor detection [11]. - As a metal element, Sc-44 can easily be labeled with various types of drugs, including peptides, antibodies, and small molecules, enhancing its versatility in pharmaceutical applications [11]. - The production process for Sc-44 is compatible with most accelerators used in hospitals, and the raw material costs are low, positioning China to compete with international standards in Sc-44 drug development [11].

Core Viewpoint - The successful domestic mass production of Scandium-44 in China marks a significant advancement in the development of new PET imaging agents for precise tumor diagnosis, indicating a promising industry outlook. Group 1: Production Achievement - The research team at the Jinan Institute of Nuclear Technology has achieved the first domestic mass production of Scandium-44, with an activity level of 100 milliCurie and a nuclear purity greater than 99% [2] - This production reduces the gap with foreign counterparts, which have been mass-producing Scandium-44 for over a decade [2] Group 2: Technical Process - The production process of Scandium-44 is complex, previously only achievable at the laboratory level in China, while foreign countries had already advanced to drug development and clinical trials [2] - The team innovated the target preparation process and independently developed the purification workflow, conducting over 50 full-process experiments and thousands of data simulations over 700 days [2][4] Group 3: Advantages of Scandium-44 - Scandium-44 is considered a superior imaging agent compared to commonly used isotopes like Fluorine-18 and Gallium-68 due to its longer half-life of approximately 4.04 hours, allowing for more flexible production and distribution [3] - Its lower positron energy results in higher imaging quality, and it can easily be labeled with various types of drugs, including peptides, antibodies, and small molecules [3] Group 4: Future Prospects - The production process developed is compatible with most accelerators used in hospitals, and the low raw material costs suggest that more hospitals and research institutions may engage in the development of Scandium-44-based drugs [4]